Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.60 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.52 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 9/20 | 0.72 |
| ▸ | AR | P10275 | 6/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11880720 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11127169 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11262672 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11070636 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11880726 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11127170 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11127550 | 0.88 | PGR (0.74) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11236326 | 0.87 | PGR (0.72) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11236322 | 0.87 | PGR (0.72) | PGRARABCB11CYP3A4NR3C1 | |
| SCHEMBL11126579 | 0.87 | PGR (0.72) | PGRARABCB11CYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744683-B1 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS | ALZA CORP (US) | 2016-03-16 | — | — | EP | claimed |
| US-8361022-B2 | Apparatus for transdermal delivery of parathyroid hormone agents | ALZA CORPORATION (US) | 2013-01-29 | — | — | US | claimed |
| US-20100152649-A1 | Apparatus and method for transdermal delivery of parathyroid hormone agents | ALZA CORPORATION (US) | 2010-06-17 | — | — | US | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| EP-1706176-A4 | FREQUENCY ASSISTED TRANSDERMAL AGENT DELIVERY METHOD AND SYSTEM | ALZA CORP (US) | 2008-06-25 | — | — | EP | claimed |
| EP-1686904-A4 | ULTRASOUND ASSISTED TRANSDERMAL VACCINE DELIVERY METHOD AND SYSTEM | ALZA CORP (US) | 2008-02-27 | — | — | EP | claimed |
| EP-1680178-A4 | SYSTEM AND METHOD FOR TRANSDERMAL VACCINE DELIVERY | ALZA CORP (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1744683-A2 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS | ALZA Corporation (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1737434-A2 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF FENTANYL-BASED AGENTS | ALZA CORPORATION (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1735469-A2 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF MULTIPLE VACCINES | ALZA Corporation (US) | 2006-12-27 | — | — | EP | claimed |
| US-20050049549-A1 | Method and device for enhancing transdermal agent flux | ALZA CORPORATION | 2005-03-03 | — | — | US | claimed |
| WO-2005016440-A1 | METHOD AND DEVICE FOR ENHANCING TRANSDERMAL AGENT FLUX | ALZA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| WO-2005016441-A1 | METHOD AND DEVICE FOR ENHANCING TRANSDERMAL AGENT FLUX | ALZA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-20050031676-A1 | Method and device for enhancing transdermal agent flux | ALZA CORPORATION | 2005-02-10 | — | — | US | claimed |
| US-20050025778-A1 | Microprojection array immunization patch and method | ALZA CORPORATION | 2005-02-03 | — | — | US | claimed |
| WO-2005002453-A1 | MICROPROJECTION ARRAY IMMUNIZATION PATCH AND METHOD | ALZA CORPORATION (US) | 2005-01-13 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | NR3C1 2322/4885PDE4D 4361/4885ADORA3 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.